Caris Life Sciences, Inc. Common Stock logo

Caris Life Sciences, Inc. Common Stock(CAI)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL
1-STAR RATING
PASS
LAST CLOSE
$23.04
11/13/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for CAI

11/13/2026: CAI (1-star) is currently NOT-A-BUY. Pass it for now.

Caris Life Sciences is a precision medicine and TechBio company specializing in molecular profiling and artificial intelligence applications for oncology. The company's primary strengths lie in its massive proprietary clinico-genomic database and comprehensive whole exome and whole transcriptome sequencing services. Its core growth story centers on expanding commercial adoption of tissue profiling and blood-based liquid biopsies alongside lucrative biopharmaceutical R&D partnerships. However, investors face notable risks including ongoing operating losses, high stock valuation sensitivity, and intense competition in molecular diagnostics. The stock is best suited for growth-oriented investors willing to tolerate high volatility while monitoring clinical execution and cash burn metrics.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorStrong fitCaris exhibits rapid top-line expansion and high operating leverage within the high-growth precision oncology market.
Momentum investorStrong fit while signal remains positiveThe stock attracts speculative and momentum trading interest around clinical data releases and quarterly earnings beats.
Value investorWeak fitTrading at an elevated P/E multiple with ongoing profitability scaling makes it unsuitable for traditional value metrics.
Dividend investorWeak fitThe company pays no dividends, focusing instead on aggressive corporate reinvestment.
Low-risk investorWeak fitHigh market volatility, a high beta, and execution risks make it a poor match for conservative capital preservation.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighThe stock experiences sharp daily and weekly price swings driven by clinical trial updates and biotech sector sentiment.
Valuation riskMedium / highGrowth expectations are heavily priced in, leaving little room for operational missteps.
Competition risk (AI and molecular diagnostics competition)HighIntense rivalry from well-funded peers like Guardant Health and Tempus AI threatens market share expansion.
Business qualityMediumProprietary database and unique whole-transcriptome sequencing give it a solid technological moat.
Dividend incomeLow / noneNo dividend yield is offered to investors seeking recurring cash flow.
Execution riskMedium / highSuccess relies heavily on scaling liquid biopsy commercialization and maintaining biopharma partnerships.

Key Highlights

Company Size Mid-Cap Stock
Market Capitalization 6.61B USD
Price to earnings Ratio 13.88
1Y Target Price 34.23
Price to earnings Ratio 13.88
1Y Target Price 34.23
Volume (30-day avg) 4.1M shares
Beta -
52 Weeks Range 14.19 - 36.50
Updated Date 11/15/2026
52 Weeks Range 14.19 - 36.50
Updated Date 11/15/2026
Dividends yield (FY) -
Basic EPS (TTM) 1.66

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
62.6%
Active BUY / eligible
72 / 115
30-Day BUY Count Change
+35
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Biotechnology

BUY participation
45.5%
Active BUY / eligible
20 / 44
30-Day BUY Count Change
+13

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Strong Uptrend
PRICE PATH

Strong Uptrend

The stock has maintained a strong upward price trend across the last three quarters.

Extreme Price Shocks
PRICE STABILITY

Extreme Price Shocks

The stock has experienced exceptionally large and disruptive price movements during the period.

Analysis of Past Performance

Type Stock
Historic Profit 4.53%
Avg. Invested days 32
Today’s Advisory PASS
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 4.0
Stock Returns Performance Upturn Returns Performance icon 1.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/13/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
CAI receives a 3-star rating, supported by solid company fundamentals, and solid analyst coverage. The rating is constrained by soft unit economics, and weak price momentum.

Company Fundamentals

★★★★★
CAI has solid overall fundamentals (4 stars), with moderate financial health, solid growth momentum, and solid ownership. In FY2025 versus FY2024, solid cash generation (FCF margin 8.2%) and strong revenue growth (+97.0%) are partially offset by negative earnings growth (-90.8%), weak profitability (net margin -66.2%).

Financial Health Rating

★★★★★
CAI's financial health is supported by solid liquidity, including working-capital and asset support (WC/assets 77.3%). Profitability is soft (2 stars), which helps explain the 3-star overall score.

Growth Momentum Score

★★★★★
Free-cash-flow growth is CAI's strongest growth driver at +126.4% FY2025 versus FY2024 (strong, 5 stars). By comparison, revenue growth (+97.0%, strong) is also strong, while earnings growth (-90.8%, negative) holds the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 58.0% and approximately 48.5% of outstanding shares are publicly tradable, supporting liquidity and institutional participation. Insider ownership of 48.92% supports management-shareholder alignment.

Top 5 Institutional Investors

FMR Inc 10.79%
J. H. Whitney Equity Partners VI, LLC 3.93%
Coatue Management LLC 3.43%
BRAIDWELL LP 2.88%
Sixth Street Partners Management Company, L.P. 2.56%

Unit Economics (Per $1K Revenue)

★★★★★
CAI generates approximately $664 of gross profit, $56 of operating income, and $82 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Moderate margins explain the 2-star rating, with weak cash conversion and weak capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: -690.09% (Tax Credit)

Quantitative Style Profile

★★★★★
CAI has a high-quality, relatively low-volatility profile. Weak momentum is the primary drawback, while valuation that is moderately attractive rather than deeply discounted.

Style Classification

Quality Focused

Quality TiltLow VolatilitySmall / Mid Cap RiskShort Squeeze Risk

How Company Makes Money

Business areaWhat it includesRetail investor read
Physician Services (Molecular Profiling)Reimbursements from insurance providers, hospitals, and clinical institutions for MI Profile and genetic testing kits.This is the core clinical diagnostic engine driving recurring day-to-day testing volume from oncologists.
Biopharma R&D SolutionsData licensing agreements, target discovery fees, and clinical trial matching services provided to pharmaceutical developers.Offers higher-margin enterprise contracts that monetize Caris's massive proprietary clinico-genomic database.
Geography (Domestic vs. International)Predominantly U.S.-based clinical operations with emerging distribution partnerships spanning Asia and Europe.The vast majority of revenue originates domestically, leaving room for international expansion over time.

Earnings Date

Report Date 2026-11-04
When After Market
Estimate 0.03
Actual 0.05

Profitability

Profit Margin 9.17%
Operating Margin (TTM) 13.35%

Management Effectiveness

Return on Assets (TTM) 7.81%
Return on Equity (TTM) 17.19%

Valuation

Trailing PE 13.88
Forward PE 31.55
Enterprise Value 6.31B
Price to Sales(TTM) 6.3
Enterprise Value 6.31B
Price to Sales(TTM) 6.3
Enterprise Value to Revenue 6.02
Enterprise Value to EBITDA 38.76
Shares Outstanding 286.78M
Shares Floating 139.06M
Shares Outstanding 286.78M
Shares Floating 139.06M
Percent Insiders 48.92
Percent Institutions 58

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.